We found that several well-known cancer genes exhibit different mutation frequencies among subtypes (Supplementary Fig. 19f), including TP53, KRAS, CDKN2A, and B2M. Upon investigation of the expression of genes in the hippo and cell cycle pathways, we found that these genes show higher expression in C1 patients (Supplementary Fig. 19g). This evidence concerns the gene CDKN2A and cancer.